Last 12 months
Inside the activity.
0 purchase rows · 7 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 6 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 18, 2026 Filed Jun 22, 2026 20:10 UTC |
Mayer HowardDirector
|
GrantStock Option (Right to Buy) · Derivative | 34,000 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001835597-26-000032 · form4.xml · derivative · entry 1 Mayer Howard · CIK 0001699610 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2036-06-17 F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting; provided, however, that all vesting shall cease if the individual ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting. Read SEC document |
| June 18, 2026 Filed Jun 22, 2026 20:13 UTC |
Wyman LisaDirector
|
GrantStock Option (Right to Buy) · Derivative | 34,000 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001835597-26-000034 · form4.xml · derivative · entry 1 Wyman Lisa · CIK 0002062689 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2036-06-17 F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting; provided, however, that all vesting shall cease if the individual ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting. Read SEC document |
| June 18, 2026 Filed Jun 22, 2026 20:06 UTC |
Dable Habib JDirector
|
GrantStock Option (Right to Buy) · Derivative | 34,000 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001835597-26-000030 · form4.xml · derivative · entry 1 Dable Habib J · CIK 0001690773 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2036-06-17 F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting; provided, however, that all vesting shall cease if the individual ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting. Read SEC document |
| June 18, 2026 Filed Jun 22, 2026 20:12 UTC |
Resnick JoshuaDirector
|
GrantStock Option (Right to Buy) · Derivative | 34,000 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001835597-26-000033 · form4.xml · derivative · entry 1 Resnick Joshua · CIK 0001690959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2036-06-17 F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting; provided, however, that all vesting shall cease if the individual ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting. F2 · ownership.direct: Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund II, and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock. Read SEC document |
| June 18, 2026 Filed Jun 22, 2026 20:03 UTC |
KEATING LAURIEDirector
|
GrantStock Option (Right to Buy) · Derivative | 34,000 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001835597-26-000028 · form4.xml · derivative · entry 1 KEATING LAURIE · CIK 0001620743 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2036-06-17 F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting; provided, however, that all vesting shall cease if the individual ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting. Read SEC document |
| June 18, 2026 Filed Jun 22, 2026 20:05 UTC |
HENSON HEIDIDirector
|
GrantStock Option (Right to Buy) · Derivative | 34,000 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001835597-26-000029 · form4.xml · derivative · entry 1 HENSON HEIDI · CIK 0001283301 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2036-06-17 F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting; provided, however, that all vesting shall cease if the individual ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting. Read SEC document |
| June 18, 2026 Filed Jun 22, 2026 20:31 UTC |
RA CAPITAL MANAGEMENT, L.P.Director · 10% owner
RA Capital Healthcare Fund LPDirector · 10% owner
RA Capital Nexus Fund II, L.P.Director
Kolchinsky PeterDirector · 10% owner
Shah Rajeev M.Director · 10% owner
|
GrantStock Option (Right to Buy) · Derivative | 34,000 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001231919-26-000684 · form4-06222026_080607.xml · derivative · entry 1 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2036-06-17 F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the Issuer's next Annual Stockholder Meeting, provided, however, that all vesting shall cease if Dr. Resnick ceases to serve as a director, unless the Issuer's Board of Directors determines that the circumstances warrant continuation of vesting. F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund II, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F3 · ownership.nature: Under Dr. Resnick's arrangement with the Adviser, Dr. Resnick holds the option for the benefit of the Fund, the Nexus Fund II and the Account. Dr. Resnick is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund, the Nexus Fund II, and the Account to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock. Read SEC document |
| June 18, 2026 Filed Jun 22, 2026 20:08 UTC |
Finer Mitchell H.Director
|
GrantStock Option (Right to Buy) · Derivative | 34,000 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001835597-26-000031 · form4.xml · derivative · entry 1 Finer Mitchell H. · CIK 0001578432 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2036-06-17 F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting; provided, however, that all vesting shall cease if the individual ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting. Read SEC document |
| May 21, 2026 Filed May 26, 2026 20:43 UTC |
Kasraian KasraChief Technical Officer
|
SaleCommon Stock | 1,233 | $1.41 | $1,739.39 |
DisclosureSEC source: 0001193125-26-239506 · ownership.xml · nonDerivative · entry 1 Kasraian Kasra · CIK 0002068538 · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,074 F1 · kind: Represents shares automatically sold by the Company on behalf of the Reporting Person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units ("RSUs"). The mandatory sale of the Reporting Person's shares was provided for in a RSU agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.41 to $1.4541, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 16:12 UTC |
Donnelly NoelChief Financial Officer
|
SaleCommon Stock | 52 | $6.33 | $328.90 |
DisclosureSEC source: 0001835597-26-000014 · form4.xml · nonDerivative · entry 2 Donnelly Noel · CIK 0001922546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,603 F1 · kind: Represents shares automatically sold by the Company on behalf of the Reporting Person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units ("RSUs"). The mandatory sale of the Reporting Person's shares was provided for in a RSU agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 16:12 UTC |
Donnelly NoelChief Financial Officer
|
SaleCommon Stock | 2,032 | $6.23 | $12,659.36 |
DisclosureSEC source: 0001835597-26-000014 · form4.xml · nonDerivative · entry 1 Donnelly Noel · CIK 0001922546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,655 F1 · kind: Represents shares automatically sold by the Company on behalf of the Reporting Person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units ("RSUs"). The mandatory sale of the Reporting Person's shares was provided for in a RSU agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 16:14 UTC |
STRECK PAULEVP, Head of R&D
|
SaleCommon Stock | 47 | $6.29 | $295.54 |
DisclosureSEC source: 0001835597-26-000016 · form4.xml · nonDerivative · entry 2 STRECK PAUL · CIK 0001708063 · EVP, Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,226 F1 · kind: Represents shares automatically sold by the Company on behalf of the Reporting Person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units ("RSUs"). The mandatory sale of the Reporting Person's shares was provided for in a RSU agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 16:14 UTC |
STRECK PAULEVP, Head of R&D
|
SaleCommon Stock | 1,832 | $6.23 | $11,413.36 |
DisclosureSEC source: 0001835597-26-000016 · form4.xml · nonDerivative · entry 1 STRECK PAUL · CIK 0001708063 · EVP, Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,273 F1 · kind: Represents shares automatically sold by the Company on behalf of the Reporting Person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units ("RSUs"). The mandatory sale of the Reporting Person's shares was provided for in a RSU agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 16:09 UTC |
McArthur James GDirector · President and CEO
|
SaleCommon Stock | 131 | $6.33 | $828.58 |
DisclosureSEC source: 0001835597-26-000012 · form4.xml · nonDerivative · entry 2 McArthur James G · CIK 0001763307 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 296,326 F1 · kind: Represents shares automatically sold by the Company on behalf of the Reporting Person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units ("RSUs"). The mandatory sale of the Reporting Person's shares was provided for in a RSU agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 16:09 UTC |
McArthur James GDirector · President and CEO
|
SaleCommon Stock | 5,144 | $6.23 | $32,047.12 |
DisclosureSEC source: 0001835597-26-000012 · form4.xml · nonDerivative · entry 1 McArthur James G · CIK 0001763307 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 296,457 F1 · kind: Represents shares automatically sold by the Company on behalf of the Reporting Person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units ("RSUs"). The mandatory sale of the Reporting Person's shares was provided for in a RSU agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 01, 2026 Filed Mar 2, 2026 17:02 UTC |
Donnelly NoelChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $6.22 | $0.00 |
DisclosureSEC source: 0001835597-26-000004 · form4.xml · derivative · entry 2 Donnelly Noel · CIK 0001922546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2036-02-29 F3 · derivative.exercise_date: This option shall vest and become exercisable as follows: 25% of the shares on the one-year anniversary of the Grant Date, with the remaining 75% vesting and becoming exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| March 01, 2026 Filed Mar 2, 2026 17:02 UTC |
Donnelly NoelChief Financial Officer
|
GrantCommon Stock | 76,793 | $0.00 | $0.00 |
DisclosureSEC source: 0001835597-26-000004 · form4.xml · nonDerivative · entry 1 Donnelly Noel · CIK 0001922546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,687 F1 · shares: Consists of 76,793 restricted stock units ("RSUs"), each representing the contingent right to receive one share of Common Stock upon vesting. The RSUs vest in equal annual installments over four years, with the first installment vesting on March 1, 2027, subject to the Reporting Person's continued service to the Issuer on each such vesting date. F2 · balance_after: Includes 11,938 shares acquired under the PepGen Inc. 2022 Employee Stock Purchase Plan on November 28, 2025 in a transaction that was exempt under Rule 16b-3(c). Read SEC document |
| March 01, 2026 Filed Mar 2, 2026 17:09 UTC |
Vittiglio JosephChief Business & Legal Officer
|
GrantStock Option (Right to Buy) · Derivative | 120,000 | $0.00 Strike: $6.22 | $0.00 |
DisclosureSEC source: 0001835597-26-000010 · form4.xml · derivative · entry 2 Vittiglio Joseph · CIK 0001551776 · Chief Business & Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2036-02-29 F2 · derivative.exercise_date: This option shall vest and become exercisable as follows: 25% of the shares on the one-year anniversary of the Grant Date, with the remaining 75% vesting and becoming exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| March 01, 2026 Filed Mar 2, 2026 17:09 UTC |
Vittiglio JosephChief Business & Legal Officer
|
GrantCommon Stock | 30,717 | $0.00 | $0.00 |
DisclosureSEC source: 0001835597-26-000010 · form4.xml · nonDerivative · entry 1 Vittiglio Joseph · CIK 0001551776 · Chief Business & Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,717 F1 · shares: Consists of 30,717 restricted stock units ("RSUs"), each representing the contingent right to receive one share of Common Stock upon vesting. The RSUs vest in equal annual installments over four years, with the first installment vesting on March 1, 2027, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| March 01, 2026 Filed Mar 2, 2026 17:05 UTC |
STRECK PAULEVP, Head of R&D
|
GrantStock Option (Right to Buy) · Derivative | 196,500 | $0.00 Strike: $6.22 | $0.00 |
DisclosureSEC source: 0001835597-26-000006 · form4.xml · derivative · entry 2 STRECK PAUL · CIK 0001708063 · EVP, Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 196,500 Underlying: Common Stock · 196,500 shares Expires 2036-02-29 F2 · derivative.exercise_date: This option shall vest and become exercisable as follows: 25% of the shares on the one-year anniversary of the Grant Date, with the remaining 75% vesting and becoming exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| March 01, 2026 Filed Mar 2, 2026 17:05 UTC |
STRECK PAULEVP, Head of R&D
|
GrantCommon Stock | 50,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001835597-26-000006 · form4.xml · nonDerivative · entry 1 STRECK PAUL · CIK 0001708063 · EVP, Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,105 F1 · shares: Consists of 50,300 restricted stock units ("RSUs"), each representing the contingent right to receive one share of Common Stock upon vesting. The RSUs vest in equal annual installments over four years, with the first installment vesting on March 1, 2027, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| March 01, 2026 Filed Mar 2, 2026 16:59 UTC |
McArthur James GDirector · President and CEO
|
GrantStock Option (Right to Buy) · Derivative | 731,250 | $0.00 Strike: $6.22 | $0.00 |
DisclosureSEC source: 0001835597-26-000002 · form4.xml · derivative · entry 2 McArthur James G · CIK 0001763307 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 731,250 Underlying: Common Stock · 731,250 shares Expires 2036-02-29 F2 · derivative.exercise_date: This option shall vest and become exercisable as follows: 25% of the shares on the one-year anniversary of the Grant Date, with the remaining 75% vesting and becoming exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| March 01, 2026 Filed Mar 2, 2026 16:59 UTC |
McArthur James GDirector · President and CEO
|
GrantCommon Stock | 187,688 | $0.00 | $0.00 |
DisclosureSEC source: 0001835597-26-000002 · form4.xml · nonDerivative · entry 1 McArthur James G · CIK 0001763307 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 301,601 F1 · shares: Consists of 187,688 restricted stock units ("RSUs"), each representing the contingent right to receive one share of Common Stock upon vesting. The RSUs vest in equal annual installments over four years, with the first installment vesting on March 1, 2027, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| March 01, 2026 Filed Mar 2, 2026 22:07 UTC |
Kasraian KasraChief Technical Officer
|
GrantStock Option (Right to Buy) · Derivative | 135,000 | $0.00 Strike: $6.22 | $0.00 |
DisclosureSEC source: 0001835597-26-000008 · form4.xml · derivative · entry 2 Kasraian Kasra · CIK 0002068538 · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 135,000 shares Expires 2036-02-29 F2 · derivative.exercise_date: This option shall vest and become exercisable as follows: 25% of the shares on the one-year anniversary of the Grant Date, with the remaining 75% vesting and becoming exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| March 01, 2026 Filed Mar 2, 2026 22:07 UTC |
Kasraian KasraChief Technical Officer
|
GrantCommon Stock | 34,557 | $0.00 | $0.00 |
DisclosureSEC source: 0001835597-26-000008 · form4.xml · nonDerivative · entry 1 Kasraian Kasra · CIK 0002068538 · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,307 F1 · shares: Consists of 34,557 restricted stock units ("RSUs"), each representing the contingent right to receive one share of Common Stock upon vesting. The RSUs vest in equal annual installments over four years, with the first installment vesting on March 1, 2027, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 17:08 UTC |
Vittiglio JosephChief Business & Legal Officer
|
GrantStock Option (Right to Buy) · Derivative | 160,000 | $0.00 Strike: $5.59 | $0.00 |
DisclosureSEC source: 0001835597-25-000009 · form4.xml · derivative · entry 2 Vittiglio Joseph · CIK 0001551776 · Chief Business & Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2035-12-07 F2 · derivative.exercise_date: This option shall vest as follows: twenty-five percent (25%) on the one-year anniversary of the Grant Date and the remainder vesting in thirty-six (36) equal monthly installments, subject to the Reporting Person's continued service or employment with the Company on each applicable vesting date. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 17:08 UTC |
Vittiglio JosephChief Business & Legal Officer
|
GrantCommon Stock | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001835597-25-000009 · form4.xml · nonDerivative · entry 1 Vittiglio Joseph · CIK 0001551776 · Chief Business & Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 F1 · date: Consists of shares of Common Stock issuable under 35,000 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal annual installments over four years with the first installment vesting on December 8, 2026, subject to the Reporting Person's continued service or employment with the Company on each applicable vesting date. Read SEC document |
| November 04, 2025 Filed Dec 18, 2025 15:28 UTC |
Donnelly NoelChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 144,000 | $0.00 Strike: $4.53 | $0.00 |
DisclosureSEC source: 0001835597-25-000013 · form4.xml · derivative · entry 8 Donnelly Noel · CIK 0001922546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,000 Underlying: Common Stock · 144,000 shares Expires 2034-02-28 F1 · kind: On November 4, 2025, the Issuer's Board of Directors approved a repricing of the Reporting Person's outstanding stock options granted under the Issuer's 2020 Stock Plan, 2022 Stock Option and Incentive Plan, and 2024 Inducement Plan. The exercise price of eligible options was reduced to $4.53, with all other terms unchanged except that the reduced exercise price is available only if the Reporting Person satisfies the applicable retention period; otherwise, the original exercise price will apply. The transactions reported herein are exempt pursuant to Rules 16b-6(d) and 16b-3 under the Securities Exchange Act of 1934. F3 · derivative.exercise_date: This option shall vest as follows: twenty-five percent (25%) on the one-year anniversary of the Grant Date and the remainder vesting in thirty-six (36) equal monthly installments, subject to the option recipient's continued service or employment with the Company on each applicable vesting date. Read SEC document |
| November 04, 2025 Filed Dec 18, 2025 15:28 UTC |
Donnelly NoelChief Financial Officer
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 144,000 | $0.00 Strike: $16.62 | $0.00 |
DisclosureSEC source: 0001835597-25-000013 · form4.xml · derivative · entry 7 Donnelly Noel · CIK 0001922546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 144,000 shares Expires 2034-02-28 F1 · kind: On November 4, 2025, the Issuer's Board of Directors approved a repricing of the Reporting Person's outstanding stock options granted under the Issuer's 2020 Stock Plan, 2022 Stock Option and Incentive Plan, and 2024 Inducement Plan. The exercise price of eligible options was reduced to $4.53, with all other terms unchanged except that the reduced exercise price is available only if the Reporting Person satisfies the applicable retention period; otherwise, the original exercise price will apply. The transactions reported herein are exempt pursuant to Rules 16b-6(d) and 16b-3 under the Securities Exchange Act of 1934. F3 · derivative.exercise_date: This option shall vest as follows: twenty-five percent (25%) on the one-year anniversary of the Grant Date and the remainder vesting in thirty-six (36) equal monthly installments, subject to the option recipient's continued service or employment with the Company on each applicable vesting date. Read SEC document |
| November 04, 2025 Filed Dec 18, 2025 15:28 UTC |
Donnelly NoelChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 144,000 | $0.00 Strike: $4.53 | $0.00 |
DisclosureSEC source: 0001835597-25-000013 · form4.xml · derivative · entry 6 Donnelly Noel · CIK 0001922546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,000 Underlying: Common Stock · 144,000 shares Expires 2033-02-28 F1 · kind: On November 4, 2025, the Issuer's Board of Directors approved a repricing of the Reporting Person's outstanding stock options granted under the Issuer's 2020 Stock Plan, 2022 Stock Option and Incentive Plan, and 2024 Inducement Plan. The exercise price of eligible options was reduced to $4.53, with all other terms unchanged except that the reduced exercise price is available only if the Reporting Person satisfies the applicable retention period; otherwise, the original exercise price will apply. The transactions reported herein are exempt pursuant to Rules 16b-6(d) and 16b-3 under the Securities Exchange Act of 1934. F3 · derivative.exercise_date: This option shall vest as follows: twenty-five percent (25%) on the one-year anniversary of the Grant Date and the remainder vesting in thirty-six (36) equal monthly installments, subject to the option recipient's continued service or employment with the Company on each applicable vesting date. Read SEC document |
| November 04, 2025 Filed Dec 18, 2025 15:28 UTC |
Donnelly NoelChief Financial Officer
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 144,000 | $0.00 Strike: $15.25 | $0.00 |
DisclosureSEC source: 0001835597-25-000013 · form4.xml · derivative · entry 5 Donnelly Noel · CIK 0001922546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 144,000 shares Expires 2033-02-28 F1 · kind: On November 4, 2025, the Issuer's Board of Directors approved a repricing of the Reporting Person's outstanding stock options granted under the Issuer's 2020 Stock Plan, 2022 Stock Option and Incentive Plan, and 2024 Inducement Plan. The exercise price of eligible options was reduced to $4.53, with all other terms unchanged except that the reduced exercise price is available only if the Reporting Person satisfies the applicable retention period; otherwise, the original exercise price will apply. The transactions reported herein are exempt pursuant to Rules 16b-6(d) and 16b-3 under the Securities Exchange Act of 1934. F3 · derivative.exercise_date: This option shall vest as follows: twenty-five percent (25%) on the one-year anniversary of the Grant Date and the remainder vesting in thirty-six (36) equal monthly installments, subject to the option recipient's continued service or employment with the Company on each applicable vesting date. Read SEC document |
| November 04, 2025 Filed Dec 18, 2025 15:28 UTC |
Donnelly NoelChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 169,037 | $0.00 Strike: $4.53 | $0.00 |
DisclosureSEC source: 0001835597-25-000013 · form4.xml · derivative · entry 4 Donnelly Noel · CIK 0001922546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 169,037 Underlying: Common Stock · 169,037 shares Expires 2032-05-05 F1 · kind: On November 4, 2025, the Issuer's Board of Directors approved a repricing of the Reporting Person's outstanding stock options granted under the Issuer's 2020 Stock Plan, 2022 Stock Option and Incentive Plan, and 2024 Inducement Plan. The exercise price of eligible options was reduced to $4.53, with all other terms unchanged except that the reduced exercise price is available only if the Reporting Person satisfies the applicable retention period; otherwise, the original exercise price will apply. The transactions reported herein are exempt pursuant to Rules 16b-6(d) and 16b-3 under the Securities Exchange Act of 1934. F3 · derivative.exercise_date: This option shall vest as follows: twenty-five percent (25%) on the one-year anniversary of the Grant Date and the remainder vesting in thirty-six (36) equal monthly installments, subject to the option recipient's continued service or employment with the Company on each applicable vesting date. Read SEC document |
| November 04, 2025 Filed Dec 18, 2025 15:28 UTC |
Donnelly NoelChief Financial Officer
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 169,037 | $0.00 Strike: $12.00 | $0.00 |
DisclosureSEC source: 0001835597-25-000013 · form4.xml · derivative · entry 3 Donnelly Noel · CIK 0001922546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 169,037 shares Expires 2032-05-05 F1 · kind: On November 4, 2025, the Issuer's Board of Directors approved a repricing of the Reporting Person's outstanding stock options granted under the Issuer's 2020 Stock Plan, 2022 Stock Option and Incentive Plan, and 2024 Inducement Plan. The exercise price of eligible options was reduced to $4.53, with all other terms unchanged except that the reduced exercise price is available only if the Reporting Person satisfies the applicable retention period; otherwise, the original exercise price will apply. The transactions reported herein are exempt pursuant to Rules 16b-6(d) and 16b-3 under the Securities Exchange Act of 1934. F3 · derivative.exercise_date: This option shall vest as follows: twenty-five percent (25%) on the one-year anniversary of the Grant Date and the remainder vesting in thirty-six (36) equal monthly installments, subject to the option recipient's continued service or employment with the Company on each applicable vesting date. Read SEC document |
| November 04, 2025 Filed Dec 18, 2025 15:28 UTC |
Donnelly NoelChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 203,339 | $0.00 Strike: $4.53 | $0.00 |
DisclosureSEC source: 0001835597-25-000013 · form4.xml · derivative · entry 2 Donnelly Noel · CIK 0001922546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 203,339 Underlying: Common Stock · 203,339 shares Expires 2031-11-10 F1 · kind: On November 4, 2025, the Issuer's Board of Directors approved a repricing of the Reporting Person's outstanding stock options granted under the Issuer's 2020 Stock Plan, 2022 Stock Option and Incentive Plan, and 2024 Inducement Plan. The exercise price of eligible options was reduced to $4.53, with all other terms unchanged except that the reduced exercise price is available only if the Reporting Person satisfies the applicable retention period; otherwise, the original exercise price will apply. The transactions reported herein are exempt pursuant to Rules 16b-6(d) and 16b-3 under the Securities Exchange Act of 1934. F2 · derivative.exercise_date: This stock option vests over four years following the vesting commencement date (October 15, 2021) with 25% of such shares vesting on the first anniversary of the vesting commencement date, and the remaining shares vesting in 36 equal monthly installments, subject to continued service through each vesting date. Read SEC document |
| November 04, 2025 Filed Dec 18, 2025 15:28 UTC |
Donnelly NoelChief Financial Officer
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 203,339 | $0.00 Strike: $10.88 | $0.00 |
DisclosureSEC source: 0001835597-25-000013 · form4.xml · derivative · entry 1 Donnelly Noel · CIK 0001922546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 203,339 shares Expires 2031-11-10 F1 · kind: On November 4, 2025, the Issuer's Board of Directors approved a repricing of the Reporting Person's outstanding stock options granted under the Issuer's 2020 Stock Plan, 2022 Stock Option and Incentive Plan, and 2024 Inducement Plan. The exercise price of eligible options was reduced to $4.53, with all other terms unchanged except that the reduced exercise price is available only if the Reporting Person satisfies the applicable retention period; otherwise, the original exercise price will apply. The transactions reported herein are exempt pursuant to Rules 16b-6(d) and 16b-3 under the Securities Exchange Act of 1934. F2 · derivative.exercise_date: This stock option vests over four years following the vesting commencement date (October 15, 2021) with 25% of such shares vesting on the first anniversary of the vesting commencement date, and the remaining shares vesting in 36 equal monthly installments, subject to continued service through each vesting date. Read SEC document |
| November 04, 2025 Filed Dec 18, 2025 15:33 UTC |
STRECK PAULEVP, Head of R&D
|
GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $4.53 | $0.00 |
DisclosureSEC source: 0001835597-25-000017 · form4.xml · derivative · entry 4 STRECK PAUL · CIK 0001708063 · EVP, Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 242,816 Underlying: Common Stock · 40,000 shares Expires 2034-08-18 F1 · kind: On November 4, 2025, the Issuer's Board of Directors approved a repricing of the Reporting Person's outstanding stock options granted under the Issuer's 2020 Stock Plan, 2022 Stock Option and Incentive Plan, and 2024 Inducement Plan. The exercise price of eligible options was reduced to $4.53, with all other terms unchanged except that the reduced exercise price is available only if the Reporting Person satisfies the applicable retention period; otherwise, the original exercise price will apply. The transactions reported herein are exempt pursuant to Rules 16b-6(d) and 16b-3 under the Securities Exchange Act of 1934. F2 · derivative.exercise_date: This option shall vest as follows: twenty-five percent (25%) on the one-year anniversary of the Grant Date and the remainder vesting in thirty-six (36) equal monthly installments, subject to the option recipient's continued service or employment with the Company on each applicable vesting date. Read SEC document |
| November 04, 2025 Filed Dec 18, 2025 15:33 UTC |
STRECK PAULEVP, Head of R&D
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $9.83 | $0.00 |
DisclosureSEC source: 0001835597-25-000017 · form4.xml · derivative · entry 3 STRECK PAUL · CIK 0001708063 · EVP, Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2034-08-18 F1 · kind: On November 4, 2025, the Issuer's Board of Directors approved a repricing of the Reporting Person's outstanding stock options granted under the Issuer's 2020 Stock Plan, 2022 Stock Option and Incentive Plan, and 2024 Inducement Plan. The exercise price of eligible options was reduced to $4.53, with all other terms unchanged except that the reduced exercise price is available only if the Reporting Person satisfies the applicable retention period; otherwise, the original exercise price will apply. The transactions reported herein are exempt pursuant to Rules 16b-6(d) and 16b-3 under the Securities Exchange Act of 1934. F2 · derivative.exercise_date: This option shall vest as follows: twenty-five percent (25%) on the one-year anniversary of the Grant Date and the remainder vesting in thirty-six (36) equal monthly installments, subject to the option recipient's continued service or employment with the Company on each applicable vesting date. Read SEC document |
| November 04, 2025 Filed Dec 18, 2025 15:33 UTC |
STRECK PAULEVP, Head of R&D
|
GrantStock Option (Right to Buy) · Derivative | 202,816 | $0.00 Strike: $4.53 | $0.00 |
DisclosureSEC source: 0001835597-25-000017 · form4.xml · derivative · entry 2 STRECK PAUL · CIK 0001708063 · EVP, Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 202,816 Underlying: Common Stock · 202,816 shares Expires 2034-08-18 F1 · kind: On November 4, 2025, the Issuer's Board of Directors approved a repricing of the Reporting Person's outstanding stock options granted under the Issuer's 2020 Stock Plan, 2022 Stock Option and Incentive Plan, and 2024 Inducement Plan. The exercise price of eligible options was reduced to $4.53, with all other terms unchanged except that the reduced exercise price is available only if the Reporting Person satisfies the applicable retention period; otherwise, the original exercise price will apply. The transactions reported herein are exempt pursuant to Rules 16b-6(d) and 16b-3 under the Securities Exchange Act of 1934. F2 · derivative.exercise_date: This option shall vest as follows: twenty-five percent (25%) on the one-year anniversary of the Grant Date and the remainder vesting in thirty-six (36) equal monthly installments, subject to the option recipient's continued service or employment with the Company on each applicable vesting date. Read SEC document |
| November 04, 2025 Filed Dec 18, 2025 15:33 UTC |
STRECK PAULEVP, Head of R&D
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 202,816 | $0.00 Strike: $9.83 | $0.00 |
DisclosureSEC source: 0001835597-25-000017 · form4.xml · derivative · entry 1 STRECK PAUL · CIK 0001708063 · EVP, Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 202,816 shares Expires 2034-08-18 F1 · kind: On November 4, 2025, the Issuer's Board of Directors approved a repricing of the Reporting Person's outstanding stock options granted under the Issuer's 2020 Stock Plan, 2022 Stock Option and Incentive Plan, and 2024 Inducement Plan. The exercise price of eligible options was reduced to $4.53, with all other terms unchanged except that the reduced exercise price is available only if the Reporting Person satisfies the applicable retention period; otherwise, the original exercise price will apply. The transactions reported herein are exempt pursuant to Rules 16b-6(d) and 16b-3 under the Securities Exchange Act of 1934. F2 · derivative.exercise_date: This option shall vest as follows: twenty-five percent (25%) on the one-year anniversary of the Grant Date and the remainder vesting in thirty-six (36) equal monthly installments, subject to the option recipient's continued service or employment with the Company on each applicable vesting date. Read SEC document |
| November 04, 2025 Filed Dec 18, 2025 15:31 UTC |
McArthur James GDirector · President and CEO
|
GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $4.53 | $0.00 |
DisclosureSEC source: 0001835597-25-000015 · form4.xml · derivative · entry 14 McArthur James G · CIK 0001763307 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2034-02-28 F1 · kind: On November 4, 2025, the Issuer's Board of Directors approved a repricing of the Reporting Person's outstanding stock options granted under the Issuer's 2020 Stock Plan, 2022 Stock Option and Incentive Plan, and 2024 Inducement Plan. The exercise price of eligible options was reduced to $4.53, with all other terms unchanged except that the reduced exercise price is available only if the Reporting Person satisfies the applicable retention period; otherwise, the original exercise price will apply. The transactions reported herein are exempt pursuant to Rules 16b-6(d) and 16b-3 under the Securities Exchange Act of 1934. F6 · derivative.exercise_date: This option shall vest as follows: twenty-five percent (25%) on the one-year anniversary of the Grant Date and the remainder vesting in thirty-six (36) equal monthly installments, subject to the option recipient's continued service or employment with the Company on each applicable vesting date. Read SEC document |
| November 04, 2025 Filed Dec 18, 2025 15:31 UTC |
McArthur James GDirector · President and CEO
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $16.62 | $0.00 |
DisclosureSEC source: 0001835597-25-000015 · form4.xml · derivative · entry 13 McArthur James G · CIK 0001763307 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 300,000 shares Expires 2034-02-28 F1 · kind: On November 4, 2025, the Issuer's Board of Directors approved a repricing of the Reporting Person's outstanding stock options granted under the Issuer's 2020 Stock Plan, 2022 Stock Option and Incentive Plan, and 2024 Inducement Plan. The exercise price of eligible options was reduced to $4.53, with all other terms unchanged except that the reduced exercise price is available only if the Reporting Person satisfies the applicable retention period; otherwise, the original exercise price will apply. The transactions reported herein are exempt pursuant to Rules 16b-6(d) and 16b-3 under the Securities Exchange Act of 1934. F6 · derivative.exercise_date: This option shall vest as follows: twenty-five percent (25%) on the one-year anniversary of the Grant Date and the remainder vesting in thirty-six (36) equal monthly installments, subject to the option recipient's continued service or employment with the Company on each applicable vesting date. Read SEC document |
| November 04, 2025 Filed Dec 18, 2025 15:31 UTC |
McArthur James GDirector · President and CEO
|
GrantStock Option (Right to Buy) · Derivative | 275,000 | $0.00 Strike: $4.53 | $0.00 |
DisclosureSEC source: 0001835597-25-000015 · form4.xml · derivative · entry 12 McArthur James G · CIK 0001763307 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2033-02-28 F1 · kind: On November 4, 2025, the Issuer's Board of Directors approved a repricing of the Reporting Person's outstanding stock options granted under the Issuer's 2020 Stock Plan, 2022 Stock Option and Incentive Plan, and 2024 Inducement Plan. The exercise price of eligible options was reduced to $4.53, with all other terms unchanged except that the reduced exercise price is available only if the Reporting Person satisfies the applicable retention period; otherwise, the original exercise price will apply. The transactions reported herein are exempt pursuant to Rules 16b-6(d) and 16b-3 under the Securities Exchange Act of 1934. F6 · derivative.exercise_date: This option shall vest as follows: twenty-five percent (25%) on the one-year anniversary of the Grant Date and the remainder vesting in thirty-six (36) equal monthly installments, subject to the option recipient's continued service or employment with the Company on each applicable vesting date. Read SEC document |
| November 04, 2025 Filed Dec 18, 2025 15:31 UTC |
McArthur James GDirector · President and CEO
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 275,000 | $0.00 Strike: $15.25 | $0.00 |
DisclosureSEC source: 0001835597-25-000015 · form4.xml · derivative · entry 11 McArthur James G · CIK 0001763307 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 275,000 shares Expires 2033-02-28 F1 · kind: On November 4, 2025, the Issuer's Board of Directors approved a repricing of the Reporting Person's outstanding stock options granted under the Issuer's 2020 Stock Plan, 2022 Stock Option and Incentive Plan, and 2024 Inducement Plan. The exercise price of eligible options was reduced to $4.53, with all other terms unchanged except that the reduced exercise price is available only if the Reporting Person satisfies the applicable retention period; otherwise, the original exercise price will apply. The transactions reported herein are exempt pursuant to Rules 16b-6(d) and 16b-3 under the Securities Exchange Act of 1934. F6 · derivative.exercise_date: This option shall vest as follows: twenty-five percent (25%) on the one-year anniversary of the Grant Date and the remainder vesting in thirty-six (36) equal monthly installments, subject to the option recipient's continued service or employment with the Company on each applicable vesting date. Read SEC document |
| November 04, 2025 Filed Dec 18, 2025 15:31 UTC |
McArthur James GDirector · President and CEO
|
GrantStock Option (Right to Buy) · Derivative | 466,095 | $0.00 Strike: $4.53 | $0.00 |
DisclosureSEC source: 0001835597-25-000015 · form4.xml · derivative · entry 10 McArthur James G · CIK 0001763307 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 466,095 Underlying: Common Stock · 466,095 shares Expires 2032-05-05 F1 · kind: On November 4, 2025, the Issuer's Board of Directors approved a repricing of the Reporting Person's outstanding stock options granted under the Issuer's 2020 Stock Plan, 2022 Stock Option and Incentive Plan, and 2024 Inducement Plan. The exercise price of eligible options was reduced to $4.53, with all other terms unchanged except that the reduced exercise price is available only if the Reporting Person satisfies the applicable retention period; otherwise, the original exercise price will apply. The transactions reported herein are exempt pursuant to Rules 16b-6(d) and 16b-3 under the Securities Exchange Act of 1934. F6 · derivative.exercise_date: This option shall vest as follows: twenty-five percent (25%) on the one-year anniversary of the Grant Date and the remainder vesting in thirty-six (36) equal monthly installments, subject to the option recipient's continued service or employment with the Company on each applicable vesting date. Read SEC document |
| November 04, 2025 Filed Dec 18, 2025 15:31 UTC |
McArthur James GDirector · President and CEO
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 466,095 | $0.00 Strike: $12.00 | $0.00 |
DisclosureSEC source: 0001835597-25-000015 · form4.xml · derivative · entry 9 McArthur James G · CIK 0001763307 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 466,095 shares Expires 2032-05-05 F1 · kind: On November 4, 2025, the Issuer's Board of Directors approved a repricing of the Reporting Person's outstanding stock options granted under the Issuer's 2020 Stock Plan, 2022 Stock Option and Incentive Plan, and 2024 Inducement Plan. The exercise price of eligible options was reduced to $4.53, with all other terms unchanged except that the reduced exercise price is available only if the Reporting Person satisfies the applicable retention period; otherwise, the original exercise price will apply. The transactions reported herein are exempt pursuant to Rules 16b-6(d) and 16b-3 under the Securities Exchange Act of 1934. F6 · derivative.exercise_date: This option shall vest as follows: twenty-five percent (25%) on the one-year anniversary of the Grant Date and the remainder vesting in thirty-six (36) equal monthly installments, subject to the option recipient's continued service or employment with the Company on each applicable vesting date. Read SEC document |
| November 04, 2025 Filed Dec 18, 2025 15:31 UTC |
McArthur James GDirector · President and CEO
|
GrantStock Option (Right to Buy) · Derivative | 40,815 | $0.00 Strike: $4.53 | $0.00 |
DisclosureSEC source: 0001835597-25-000015 · form4.xml · derivative · entry 8 McArthur James G · CIK 0001763307 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,815 Underlying: Common Stock · 40,815 shares Expires 2032-03-06 F1 · kind: On November 4, 2025, the Issuer's Board of Directors approved a repricing of the Reporting Person's outstanding stock options granted under the Issuer's 2020 Stock Plan, 2022 Stock Option and Incentive Plan, and 2024 Inducement Plan. The exercise price of eligible options was reduced to $4.53, with all other terms unchanged except that the reduced exercise price is available only if the Reporting Person satisfies the applicable retention period; otherwise, the original exercise price will apply. The transactions reported herein are exempt pursuant to Rules 16b-6(d) and 16b-3 under the Securities Exchange Act of 1934. F5 · derivative.exercise_date: This stock option vests over four years following the vesting commencement date (March 7, 2022) with 25% of such shares vesting on the first anniversary of the vesting commencement date, and the remaining shares vesting in 36 equal monthly installments, subject to continued service through each vesting date. Read SEC document |
| November 04, 2025 Filed Dec 18, 2025 15:31 UTC |
McArthur James GDirector · President and CEO
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 40,815 | $0.00 Strike: $11.23 | $0.00 |
DisclosureSEC source: 0001835597-25-000015 · form4.xml · derivative · entry 7 McArthur James G · CIK 0001763307 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,815 shares Expires 2032-03-06 F1 · kind: On November 4, 2025, the Issuer's Board of Directors approved a repricing of the Reporting Person's outstanding stock options granted under the Issuer's 2020 Stock Plan, 2022 Stock Option and Incentive Plan, and 2024 Inducement Plan. The exercise price of eligible options was reduced to $4.53, with all other terms unchanged except that the reduced exercise price is available only if the Reporting Person satisfies the applicable retention period; otherwise, the original exercise price will apply. The transactions reported herein are exempt pursuant to Rules 16b-6(d) and 16b-3 under the Securities Exchange Act of 1934. F5 · derivative.exercise_date: This stock option vests over four years following the vesting commencement date (March 7, 2022) with 25% of such shares vesting on the first anniversary of the vesting commencement date, and the remaining shares vesting in 36 equal monthly installments, subject to continued service through each vesting date. Read SEC document |
| November 04, 2025 Filed Dec 18, 2025 15:31 UTC |
McArthur James GDirector · President and CEO
|
GrantStock Option (Right to Buy) · Derivative | 40,815 | $0.00 Strike: $4.53 | $0.00 |
DisclosureSEC source: 0001835597-25-000015 · form4.xml · derivative · entry 6 McArthur James G · CIK 0001763307 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,815 Underlying: Common Stock · 40,815 shares Expires 2031-09-05 F1 · kind: On November 4, 2025, the Issuer's Board of Directors approved a repricing of the Reporting Person's outstanding stock options granted under the Issuer's 2020 Stock Plan, 2022 Stock Option and Incentive Plan, and 2024 Inducement Plan. The exercise price of eligible options was reduced to $4.53, with all other terms unchanged except that the reduced exercise price is available only if the Reporting Person satisfies the applicable retention period; otherwise, the original exercise price will apply. The transactions reported herein are exempt pursuant to Rules 16b-6(d) and 16b-3 under the Securities Exchange Act of 1934. F4 · derivative.exercise_date: This stock option vests over four years following the vesting commencement date (October 6, 2021) with 25% of such shares vesting on the first anniversary of the vesting commencement date, and the remaining shares vesting in 36 equal monthly installments, subject to continued service through each vesting date. Read SEC document |
| November 04, 2025 Filed Dec 18, 2025 15:31 UTC |
McArthur James GDirector · President and CEO
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 40,815 | $0.00 Strike: $8.96 | $0.00 |
DisclosureSEC source: 0001835597-25-000015 · form4.xml · derivative · entry 5 McArthur James G · CIK 0001763307 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,815 shares Expires 2031-09-05 F1 · kind: On November 4, 2025, the Issuer's Board of Directors approved a repricing of the Reporting Person's outstanding stock options granted under the Issuer's 2020 Stock Plan, 2022 Stock Option and Incentive Plan, and 2024 Inducement Plan. The exercise price of eligible options was reduced to $4.53, with all other terms unchanged except that the reduced exercise price is available only if the Reporting Person satisfies the applicable retention period; otherwise, the original exercise price will apply. The transactions reported herein are exempt pursuant to Rules 16b-6(d) and 16b-3 under the Securities Exchange Act of 1934. F4 · derivative.exercise_date: This stock option vests over four years following the vesting commencement date (October 6, 2021) with 25% of such shares vesting on the first anniversary of the vesting commencement date, and the remaining shares vesting in 36 equal monthly installments, subject to continued service through each vesting date. Read SEC document |
| November 04, 2025 Filed Dec 18, 2025 15:31 UTC |
McArthur James GDirector · President and CEO
|
GrantStock Option (Right to Buy) · Derivative | 40,815 | $0.00 Strike: $4.53 | $0.00 |
DisclosureSEC source: 0001835597-25-000015 · form4.xml · derivative · entry 4 McArthur James G · CIK 0001763307 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,815 Underlying: Common Stock · 40,815 shares Expires 2031-09-05 F1 · kind: On November 4, 2025, the Issuer's Board of Directors approved a repricing of the Reporting Person's outstanding stock options granted under the Issuer's 2020 Stock Plan, 2022 Stock Option and Incentive Plan, and 2024 Inducement Plan. The exercise price of eligible options was reduced to $4.53, with all other terms unchanged except that the reduced exercise price is available only if the Reporting Person satisfies the applicable retention period; otherwise, the original exercise price will apply. The transactions reported herein are exempt pursuant to Rules 16b-6(d) and 16b-3 under the Securities Exchange Act of 1934. F3 · derivative.exercise_date: This stock option vests over four years following the vesting commencement date (September 17, 2021) with 25% of such shares vesting on the first anniversary of the vesting commencement date, and the remaining shares vesting in 36 equal monthly installments, subject to continued service through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.